Gaia therapeutics
WebMar 27, 2024 · Hamburg, Tuesday 27 March 2024 09.00 GMT. GAIA’s fully automated therapy software, Elevida, reduces Multiple Sclerosis (MS) related fatigue in patients, a randomized controlled trial (RCT) has … WebFeb 15, 2024 · GAIA BioMedicine, Inc., was founded in 2015 by Prof Yoshikazu Yonemitsu (Graduate school of Kyushu University) as a spin-off venture of Kyushu University. Now a clinical-stage, technology-driven...
Gaia therapeutics
Did you know?
WebApr 20, 2024 · The collaboration is set to highlight the maturation of digital medicine and the strategic clinical implications of digital therapeutics for biopharma clinical and commercial teams, the companies... WebApr 14, 2024 · Recently Concluded Data & Programmatic Insider Summit March 22 - 25, 2024, Scottsdale Digital OOH Insider Summit February 19 - 22, 2024, La Jolla
WebGAIA AG is one of the world’s leading companies in the field of digital health. We combine scientific, technological and therapeutic expertise under one roof. Our partners include well-known pharmaceutical companies, health insurance providers, medical research organizations and leading universities in Europe, the USA and Asia. Vacancies Benefits: WebAug 20, 2024 · GAIA AG Dr. Mario Weiss, CEO Tel: +49.40.351 05 20 E-mail: [email protected] or Dr. Matthias Zenker, SVP Business Development DTx Tel: +49.40.351 05 20 E-mail: [email protected] About Orexo Orexo develops improved pharmaceuticals based on innovative drug delivery technologies.
WebOct 18, 2024 · The paper is authored by Bjorn Meyer, Ph.D. (GAIA Therapeutics), Geri-Lynn Utter, Psy.D. (Orexo US)., and Catherine Hillman, Psy.D. MODIA ™ is a prescription digital therapeutic that has not been evaluated by the FDA (not FDA-cleared). It is marketed under the FDA's digital health device emergency use guidance (136939).
WebFeb 15, 2024 · GAIA BioMedicine, Inc., was founded in 2015 by Prof Yoshikazu Yonemitsu (Graduate school of Kyushu University) as a spin-off venture of Kyushu University. Now …
WebKaia Health is a digital therapeutics company that creates evidence-based treatments for a range of disorders including back pain and COPD. Working with experts in various medical fields, the company uses machine learning to deliver individualized app interventions that aim to empower and motivate patients to take control and self-manage their hatch match dispatchWebAt GAIA we are focused on the development of evidence-based, safe and accessible digital therapeutics that help patients restore and maintain their mental and physical health. … GAIA's digital therapeutics have demonstrated their clinical benefit in … Multiple career opportunities in a growth industry: GAIA AG is one of the world's … In 2016, GAIA licensed deprexis to the global pharmaceutical company, … hatchmate egg incubatorWebEthypharm Digital Therapy - Pioneer in digital therapies Our ambition: to become a European leader in digital therapies The Digital Therapy “era” is here From wellbeing applications to telemedicine, digital health offers are numerous and diverse. Within e-health, Prescription Digital Therapies (DTx) are growing in importance. booties square toeWebMar 6, 2024 · A computer program from GAIA Therapeutics has been clinically demonstrated in randomized controlled trials to be as effective as drugs for treating depression linked to multiple sclerosis, for ... booties to keep carpet cleanWebWe enjoy sharing alternative health education options, empowering you and your loved ones to thrive. Gaia’s Pharmacy offer essential oil blends for first aid, athletic injuries, family health, recovery from surgeries, stress … booties tf2WebPharmaceutical company Orexo has partnered with digital therapeutics developer Gaia to create a new digital therapy (DTx) for people with opioid use disorder (OUD).. Under the terms of the agreement, Orexo will hold exclusive worldwide commercial rights to the product, OXD-01, which is expected to be launched in the US in 2024. hatch maternity black blouseWebOct 18, 2024 · MODIA ™ was developed by Orexo in collaboration with GAIA Therapeutics, and, in July, Orexo was pleased to announce the enrollment of the first participant in a clinical evaluation of MODIA ™ for the treatment of OUD as part of a clinician-supervised MAT program. booties slippers for women